

BRAINWARE UNIVERSITY

Term End Examination 2021 - 22 Programme – Bachelor of Pharmacy Course Name - Pharmacovigilance **Course Code - BP805ET** (Semester VIII)

Time allotted: 1 Hrs.30 Min. Full Marks: 75

[The figure in the margin indicates full marks.]

Group-A

(Multiple Choice Type Question) 1 x 75=75

Choose the correct alternative from the following:

Choose the correct alternative from the following	<i>:</i>
(1) Which of the following is not related to the AD	OR type A?
a) It is predictable	b) It is dose related
c) It is pharmacodynamic effect	d) It occurs due to genetic
(2) Sulfanilamide tragedy occurred in the year	
a) 1938	b) 1937
c) 1951	d) 1838
(3) Phocomelia related to	
a) Sulfanilade	b) Sulfa drugs
c) Alcohol	d) Thalidomide
(4) PvPI stands for	
a) Pharmacovigilance Power of India	b) Pharmacovigilance Program of India
c) International Program of Pharmacovigilanc e	d) None
(5) Which of the following is not related to Type I	Preaction?
a) Accumulation of drug	b) Chemotherapy secondary tumor
c) Analgesic nephropathy	d) Anaphylaxis
(6) Type I ADR reaction is caused	
a) IgE mediated	b) By tissue injury
c) When T cell bind to a specific antigen	d) By cytotoxic antibodies
(7) Idiosyncarsy is related to	
a) Anaphylaxis	b) Genetically determined effects
c) Allergic reaction	d) Cytotoxic antibodies

(8) GPP stands for	
a) Good Pharmacovigilance Practice	b) Good Pharmacy Practice
c) Good Pharma Product	d) Guidelines for Pharmaceutical Product
(9) is defined unintended effects oc	curring at normal dose of medication.
a) ADR	b) Side effects
c) Adverse event	d) None
(10) CDSCO stands for	
a) Central Drugs Standard Control Organizati on	b) Central Drugs Safety Control Office
c) Central Drugs Safety Control Organization	d) Central Directory for Safety and Control of Organization
(11) Commonly reported ADR of diuretic class of	drugs.
a) Alopecia	b) Hypokalemia
c) Skin cancer	d) Rhinitis
(12) That part of quality assurance which ensures the and controlled to the quality standards appropriate the controlled	• •
a) Gap analysis	b) Drug master file
c) Good manufacturing practices	d) Inter company transfer
(13) What is the purpose of the case report form?	
 a) To ensure data accuracy by providing a pla ce to store warehouse patient data for audit purposes 	b) To provide a reference for all study subject s from which to analyze patient data
c) To include in the NDA filing	d) All of these
(14) What is the primary focus of Phase 3 Clinical	testing?
a) How to manage costs	b) The collection and analysis of highly specif ic efficacy end-point data
c) The optimal range of effective dosage	d) The analysis of data results from the small-subset target population
(15) Full form of BLA is	
a) Biologic license application	b) Biologic law application
c) Biologic license abbreviation	d) Biologic law abbreviation
(16) The is the means through whis s exemption from the FDA.	ich the sponsor technically obtains thi
a) AND	b) AIND
c) INDA	d) IND
(17) The main components of ICSR is/ are	
a) An identifiable patient	b) An adverse event
c) Susceptible drug	d) All of these
(18) In pharmacovigilance the term ADR stands fo	r
a) Adverse Drug Reaction	b) Adverse Dose Reaction
c) Absolute Drug Reaction	d) Absolute Dose Reaction
(19) Animal studies, clinical trials, bioavailability s	studies are part of which application p

a) NDA	b) IND
c) ANDA	d) BLA
(20) What is the importance of preclinical phase?	
 a) To determine pharmacokinetics and pharm acodynamics 	b) Dose range and efficacy
c) Non human trial	d) None
(21) MedDRA is developed by	
a) WHO	b) ICH
c) CDSCO	d) WHO-UMC
(22) is an adverse event report for a ata in pharmacovigilance	nn individual patient and is source of d
a) Drug reaction	b) ICSR
c) Teratogenicity	d) None
(23) PSUR stands for	
a) Periodic safety update report	b) Public safety update report
c) Pacific survey on user report	d) None
(24) Mutual acceptance between	
a) Europe	b) Japan
c) US	d) All of these
(25) IRB stands for	
a) Ireland Recruitment Board	b) Institutional Review Board
c) International Research Board	d) International Reserve Bank
(26) CTD stands for	
a) Computer tomographic design	b) Common technical document
c) Council of technical department	d) Common technical department
(27) The oldest quality control laboratory of the Dr	rug Control Authorities in India is
a) Central Drugs Testing Laboratory, Kolkata	b) Central Drugs Testing Laboratory, Chenna i, Tamil Nadu
c) Central Drugs Testing Laboratory, Hyderab ad, AP	d) Central Drugs Testing Laboratory, Mumbai
(28) Periodic benefit risk evaluation report describe	ed in the
a) ICH-E2C	b) ICH-B2B
c) ICH-EC	d) None
(29) Inspection is a part of the	
a) Quality planning	b) Quality circle
c) Quality improvement	d) Quality assurance and quality control
(30) Clinical studies come under	
a) Quality guidelines	b) Safety guidelines
c) Efficacy guidelines	d) All of these
(31) Stability testing comes under	
a) Quality guidelines	b) Safety guidelines
c) Efficacy guidelines	d) All of these

(32) Pharmacovigilance activities, especially in preperiod of a new drug is known as	
a) A2C	b) E2E Pharmacovigilance
c) ABC	d) None
reactions, which are not directly n) but can unusual patient phenotype.	ctly related to drug dose (concentratio
a) Adverse drug	b) Carcinogenic
c) Idiosyncrasy	d) All of these
(34) Full form of ABC related to the drug transporter	er is
a) ATP based casual transporter	b) ADP binding cassette transporter
c) ATP binding cassette transporter	d) None of these
(35) Drugs metabolizing enzymes are also called as	
a) Metabolic biomarker	b) Reducer
c) Oxidizing agent	d) None of these
(36) The study of single genetic variations and their macokinetic and pharmacodynamics response	
a) Pharmacodynamic	b) Pharmacokinetics
c) Pharmacogenomics	d) Pharmacogenetics
(37) The correct way(s) of data collection	•
a) Spontaneous reports	b) Questionnaires
c) Elicited reports	d) All of these
(38) What is the full form of PDCO?	
a) Pediatric committee	b) Paramedical and doctors cooperative
c) Pacific and developed countries organizati on	d) None of these
(39) Number of groups working in CIOMS.	
a) 8	b) 4
c) 12	d) 13
(40) CDSCO is headed by	
a) DCGI	b) DCC
c) Govt of India	d) Ministry of family and health welfare
(41) Rules 122A is permission for	
 a) To conduct clinical trial for investigational new drug 	b) To import new drug
c) Definition of new drug	d) To manufacture new drug
(42) Rules 122DA is permission for	
 a) To conduct clinical trial for investigational new drug 	b) To import new drug
c) Definition of new drug	d) To manufacture new drug
(43) MedDRA and DILI are the recent working gro	ups for which organization?
a) WHO	b) CIOMS
c) CDSCO	d) ICMR
(44) What is the correct age group for pediatric pati	ents?

a) 1-6 years	b) From birth to 18 years
c) From birth to 19 years	d) None of these
(45) Schedule P is known as	
a) Packaging of drugs	b) Provisional application
c) Colour pigments	d) Life period of drugs
(46) Detailed information concerning a specific factory he drug regulatory authority, intended for the inmarketing authorization known as	• •
a) Gap analysis	b) Drug master file
c) Inter company transfer	d) Good manufacturing practices
(47) Full form of CFR is	
a) Code of federal rules	b) Code of federal regulations
c) Civil federal regulations	d) Civil federal rules
(48) ICD stands for	
a) Indian Classification of Disease	b) Inter Continental Diseases
c) Indian Council of Drugs	d) International Classification of Diseases
(49) As per ATC, drugs are classified intole	vels.
a) 10	b) 14
c) 4	d) 5
(50) INN stands for	
a) International nonproprietary names for dru gs	b) International nonpotent names for drugs
c) Indian national names	d) None of these
(51) Drug regulatory agency of country Australia	
a) TGA	b) MCC
c) MHRA	d) ANVISA
(52) All medicines sold in South Africa must be reg	gistered by
a) TGA	b) MCC
c) MHRA	d) ANVISA
(53) Identify the relevant regulatory body in USFD.	A for approval of drugs.
a) BLA	b) IND
c) CBER	d) CDER
(54) In Europe, variations are classified as Type-IA	forchange
a) Minor	b) Major
c) Moderate	d) Relative
(55) Which of the following is an International regu	latory authority for drug regulation?
a) CDSCO	b) WHO
c) US-FDA	d) EMA
(56) In PCT, patent application enters national phas	e at months.
a) 12	b) 24
c) 30	d) 36
(57) The guideline ICH Q1A (R2) refers to	

 a) Stability study of new molecular entities an d associated drug products 	b) Generation of photostability information
c) Analytical validation	d) Impurities
(58) Prior to 2004, EMA was known as	
a) European Agency for the Evaluation of Me dicinal Products	b) European Medicines External Agency
c) European Medicine Examination and Asse ssment	d) European Medicine Examination Agency
(59) If any organization wishes to market their procedure.	duct only in one EU country then
a) National Procedures	b) Mutual recognition Procedure
c) Centralized Procedure	d) Decentralized Procedure
(60) product does not require a BLA	
a) Serum	b) Glucagon
c) Blood, blood component or derivative	d) Vaccine
(61) The headquarter of the WTO is located at	
a) Geneva	b) Belgium
c) Austria	d) Czech
nt the onward spread of disease within the pop	
a) Immunization	b) Vaccination
c) ADR monitoring	d) Option a and b
(63) Based on antigen numbers, vaccine may be cla	assified as
a) Monovalent	b) Polyvalent or multivalent
c) Both a and b	d) None
(64) Which one is not a type of live attenuated vacc	cine?
a) BCG	b) Hepatitis A
c) Oral polio vaccine	d) Rotavirus vaccine
(65) Types of vaccine	
a) LAV	b) Toxoid
c) Subunit	d) All of these
(66) Which of the following AEFIs would be classi	ified as a 'severe reaction'?
a) Vomiting, 5 minutes after receiving a BCG vaccination.	b) Fainting, 5 minutes after receiving a DTP v accination.
c) Anaphylaxis, 5 minutes after receiving an I nfluenza-A vaccination.	d) Loss of appetite, 4 days after BCG vaccinat ion.
(67) Which of the following onset intervals of seve tion is probably not due to the given vaccine?	re adverse events following immuniza
a) Febrile seizures occurring 6–12 days follo wing measles vaccination.	b) Anaphylaxis occuring 2–3 days after MMR vaccination.
c) Thrombocytopenia occurring 15–35 days a fter measles vaccine.	d) Vaccine-associated paralytic poliomyelitis (VAPP) occurring 4–30 days after OPV.
(68) Which option is/are methods of pharmacovigil	lance?

a) Overview of clinical trials	b) Post marketing surveillance
c) Laboratory access	d) All of these
(69) Which option is incorrect in regard to vaccine f	failure?
a) Age	b) Overweight
c) Infections	d) Immunity
(70) Astudy is constituted when data is col g a specified interval of time or exposure of dis	
a) Case study	b) Study of patients
c) Cohort study	d) Cross survey study
(71) According to surveillance the repo th related events. It is a very common type of s	rts describe AR, disease risk and heal urveillance.
a) Active	b) Passive
c) Stimulated reporting	d) None
(72) communication is held between hea	1.1 6 1 1 1
(72)communication is held between hea uthorization holders about the desired informat	
uthorization holders about the desired informat	ion.
uthorization holders about the desired informat a) Professional	ion. b) Passive d) Personal
uthorization holders about the desired informat a) Professional c) Effective	ion. b) Passive d) Personal
uthorization holders about the desired informat a) Professional c) Effective (73) Who is responsible for WHO international drug	ion. b) Passive d) Personal g monitoring Programme?
uthorization holders about the desired informat a) Professional c) Effective (73) Who is responsible for WHO international drug a) Uppsala Monitoring Center	ion. b) Passive d) Personal g monitoring Programme? b) FDA
uthorization holders about the desired informat a) Professional c) Effective (73) Who is responsible for WHO international drug a) Uppsala Monitoring Center c) EU	ion. b) Passive d) Personal g monitoring Programme? b) FDA
uthorization holders about the desired informat a) Professional c) Effective (73) Who is responsible for WHO international drug a) Uppsala Monitoring Center c) EU (74) Sentinel system was launched by FDA in -	ion. b) Passive d) Personal g monitoring Programme? b) FDA d) Japan
uthorization holders about the desired informat a) Professional c) Effective (73) Who is responsible for WHO international drug a) Uppsala Monitoring Center c) EU (74) Sentinel system was launched by FDA in - a) 2008	b) Passive d) Personal g monitoring Programme? b) FDA d) Japan b) 2001 d) 2009
uthorization holders about the desired informat a) Professional c) Effective (73) Who is responsible for WHO international drug a) Uppsala Monitoring Center c) EU (74) Sentinel system was launched by FDA in - a) 2008 c) 2010	b) Passive d) Personal g monitoring Programme? b) FDA d) Japan b) 2001 d) 2009